BRIEF-Allergan receives refusal to file letter from FDA for Vraylar SNDA
September 22, 2017 at 16:53 PM EDT
* Allergan receives refusal to file letter from FDA for Vraylar (Cariprazine) supplemental new drug application (SNDA) for the treatment of negative symptoms in Schizophrenia
